An open, phase I study of cediranib in patients with acute myeloid leukemia (AML)

被引：0

作者：

Fiedler, Walter ^{[1
]}

Mesters, Rolf ^{[2
]}

Heuser, Michael ^{[3
]}

Ehninger, Gerhard ^{[4
]}

Ottman, Oliver G. ^{[5
]}

Berdel, Wolfgang E. ^{[2
]}

Zirrgiebel, Ute ^{[6
]}

Robertson, Jane ^{[7
]}

Puchalski, Thomas A. ^{[8
]}

Brave, Sandra R. ^{[7
]}

Juergensmeier, Juliane M. ^{[7
]}

Serve, Hubert ^{[2
,5
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Hosp, Munster, Germany

[3] Hannover Med Sch, D-3000 Hannover, Germany

[4] Univ Hosp Carl Gustav Carus, Dresden, Germany

[5] Univ Hosp, Frankfurt, Germany

[6] ProQinase GmbH, Freiburg, Germany

[7] AstraZeneca, Macclesfield, Cheshire, England

[8] AstraZeneca, Wilmington, DE USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.895.895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

895

引用

页码：273A / 273A

页数：1

共 50 条

[31] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
Navada, Shyamala C.
Odchimar-Reissig, Rosalie
Reddy, E. Premkumar
Holland, James F.
Wilhelm, Francois
Silverman, Lewis R.
BLOOD, 2012, 120 (21)
[32] A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)
Howard, Dianna
Liesveld, Jane
Phillips, Gordon L., II
Guzman, Monica L.
Jordan, Craig T.
BLOOD, 2008, 112 (11) : 1014 - 1014
[33] Phase I study of low dose decitabine in patients with acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity.
Blum, W
Bruner-Klisovic, R
Liu, SJ
Byrd, JC
Liu, ZF
Chan, KK
Kefauver, C
Huynh, L
Grever, MR
Marcucci, G
BLOOD, 2005, 106 (11) : 529A - 529A
[34] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
Daver, Naval
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Pemmaraju, Naveen
Kadia, Tapan
DiNardo, Courtney
Jain, Nitin
Borthakur, Gautum
Cortes, Jorge
Adam, Craig
Ravandi, Farhad
CANCER RESEARCH, 2014, 74 (19)
[35] A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy
Brandwein, Joseph M.
Seki, Jack T.
Atenafu, Eshetu G.
Rostom, Amr
Lutynski, Andrzej
Rydlewski, Anna
Schimmer, Aaron D.
Schuh, Andre C.
Gupta, Vikas
Yee, Karen W. L.
SUPPORTIVE CARE IN CANCER, 2019, 27 (06) : 2295 - 2300
[36] A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy
Joseph M. Brandwein
Jack T. Seki
Eshetu G. Atenafu
Amr Rostom
Andrzej Lutynski
Anna Rydlewski
Aaron D. Schimmer
Andre C. Schuh
Vikas Gupta
Karen W. L. Yee
Supportive Care in Cancer, 2019, 27 : 2295 - 2300
[37] INTENSIVE TREATMENT OF PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)
MULDER, NH
DEVRIES, EGE
HOUWEN, B
NETHERLANDS JOURNAL OF MEDICINE, 1980, 23 (04): : 179 - 179
[38] AngioCRIME in Acute Myeloid Leukemia (AML)
Macintyre, Elizabeth
HEMASPHERE, 2017, 1 (01):
[39] Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)
Nolt, Dawn
Lindemulder, Susan
Meyrowitz, Jeffrey
Chang, Bill H.
Malempati, Suman
Thomas, Gregory
Stork, Linda
PEDIATRIC BLOOD & CANCER, 2015, 62 (07) : 1149 - 1154
[40] VITAMIN C DEFICIENCY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Ottone, T.
Faraoni, I.
Fucci, G.
Divona, M.
De Bellis, E.
Marchesi, F.
Angelini, D. F.
Palmieri, R.
Gurnari, C.
Giansanti, M.
Nardozza, A. M.
Montesano, F.
Travaglini, S.
Puzzangara, M. C.
De Angelis, G.
Cicconi, L.
De Bardi, M.
Battistini, L.
Massoud, R.
Venditti, A.
Voso, M. T.
HAEMATOLOGICA, 2021, 106 (10) : 96 - 97

← 1 2 3 4 5 →